GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzamend Neuro Inc (NAS:ALZN) » Definitions » Operating Margin %

Alzamend Neuro (Alzamend Neuro) Operating Margin % : 0.00% (As of Jan. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alzamend Neuro Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Alzamend Neuro's Operating Income for the three months ended in Jan. 2024 was $-2.66 Mil. Alzamend Neuro's Revenue for the three months ended in Jan. 2024 was $0.00 Mil. Therefore, Alzamend Neuro's Operating Margin % for the quarter that ended in Jan. 2024 was 0.00%.

The historical rank and industry rank for Alzamend Neuro's Operating Margin % or its related term are showing as below:


ALZN's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -155.93
* Ranked among companies with meaningful Operating Margin % only.

Alzamend Neuro's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Alzamend Neuro's Operating Income for the three months ended in Jan. 2024 was $-2.66 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jan. 2024 was $-12.39 Mil.


Alzamend Neuro Operating Margin % Historical Data

The historical data trend for Alzamend Neuro's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alzamend Neuro Operating Margin % Chart

Alzamend Neuro Annual Data
Trend Apr19 Apr20 Apr21 Apr22 Apr23
Operating Margin %
- - - - -

Alzamend Neuro Quarterly Data
Apr19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alzamend Neuro's Operating Margin %

For the Biotechnology subindustry, Alzamend Neuro's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alzamend Neuro's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzamend Neuro's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Alzamend Neuro's Operating Margin % falls into.



Alzamend Neuro Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Alzamend Neuro's Operating Margin % for the fiscal year that ended in Apr. 2023 is calculated as

Operating Margin %=Operating Income (A: Apr. 2023 ) / Revenue (A: Apr. 2023 )
=-14.87 / 0
= %

Alzamend Neuro's Operating Margin % for the quarter that ended in Jan. 2024 is calculated as

Operating Margin %=Operating Income (Q: Jan. 2024 ) / Revenue (Q: Jan. 2024 )
=-2.66 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alzamend Neuro  (NAS:ALZN) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Alzamend Neuro Operating Margin % Related Terms

Thank you for viewing the detailed overview of Alzamend Neuro's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alzamend Neuro (Alzamend Neuro) Business Description

Traded in Other Exchanges
N/A
Address
3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Executives
Ault Milton C Iii 10 percent owner 11411 SOUTHERN HIGHLANDS PARKWAY, SUITE 240, LAS VEGAS NV 89141
David J Katzoff officer: Chief Operating Officer 201 SHIPYARD WAY, NEWPORT BEACH CA 92663
Stephan Jackman director, officer: Chief Executive Officer C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Lynne Fahey Mcgrath director 28145 CEDAR POINT RD., EASTON MD 21601
Mark Gustafson director 10691 ROSECROFT CRESCENT, RICHMOND A1 V7A 2H9
William B. Horne director C/O AULT ALLIANCE, INC., 940 SOUTH COAST DRIVE, SUITE 200, COSTA MESA CA 92626
Henry Carl Nisser director, officer: Exec VP and General Counsel 100 PARK AVENUE, SUITE 1658A, NEW YORK NY 10017
Kenneth S Cragun officer: SVP of Finance 3775 CHIPPEWA CIRCLE, CORONA CA 92881
Jeffrey Oram director 15 ORCHARD STREET, MENDHAM NJ 07945
Escalona Lien officer: Chief Financial Officer C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Andrew H. Woo director 2021 SANTA MONICA BLVD., SUITE 525E, SANTA MONICA CA 90404

Alzamend Neuro (Alzamend Neuro) Headlines

From GuruFocus

Alzamend Neuro to Present at Sequire Biotechnology Conference

By Business Wire Business Wire 01-26-2023

Alzamend Neuro Announces Reverse Stock Split

By Business Wire 10-30-2023